News
Singapore-UK Team To Develop a Novel Device to Reduce Chemotherapy Side-Effects
A team of clinicians and scientists from the National University Cancer Institute, Singapore (NCIS) at the National University Hospital (NUH) and the N.1 Institute for Health at the National University of Singapore (NUS) has partnered Paxman Coolers Ltd (UK)...
News
Ashfield Advisory takes strategic step forward with two new additions to senior leadership team
Ashfield Advisory, an ecosystem of healthcare advisory and consulting businesses, part of UDG Healthcare plc., has announced two senior leadership appointments.
Mary-Kate McGarry joins in the new position of Vice President of Strategy and Emer Jameson, steps into the role...
News
Vibalogics invests an additional $50 million to further expand cGMP manufacturing capacity for viral vectors
Vibalogics, a global contract development and manufacturing organization (CDMO), has today announced that it has initiated the first stage of a planned $50 million dollar investment at its Cuxhaven, Germany facility, expanding early-to-late phase clinical virotherapy manufacturing capacity.
The investment...
News
MaxiVision Eye Hospitals launches Mucormycosis (Black Fungus) Early Detection Center
MaxiVision Eye Hospitals group, the pioneers in the industry of eye care medical services have launched “Mucormycosis (Black Fungus) Early Detection Center” at its Somajiguda Branch in Hyderabad to identify the virulent fungal infection in its initial stage preventing...
Drug Research
mCureX and Samyang sign MoU for mRNA vaccine development
OliX Pharmaceuticals’ subsidiary mCureX has entered a memorandum of understanding (MoU) with Samyang Holdings to develop a messenger ribonucleic acid (mRNA) vaccine for Covid-19.
The companies are co-developing a vaccine that could potentially target Covid-19 viral variants.
According to the deal,...
Drug Research
AGC Biologics Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.
“We are honored...
News
U.S. FDA Approves PREVNAR 20, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older
Pfizer Inc. announced that the U.S. FDA has approved PREVNAR 20™ for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read